Funding profile · Digital biology, drug discovery

Anto Biosciences

A Y Combinator Fall 2025 company with an announced seed round and no confirmed dollar total. Here is what the public record shows, and where the announcements do not line up.

UndisclosedSeed round size, no source confirms an amount
8Investors named across two separate seed announcements
0Form D filings found under Anto Biosciences, Inc. on SEC EDGAR
0NIH or NSF awards found naming this company

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Fall 2025 Y Combinator, Fall 2025 batch Not disclosed Y Combinator YC data
By early 2026 Seed, per 007 Venture Partners Not disclosed Y Combinator, Massive Tech Ventures, Ritual Capital, RRE Ventures, Standard Partners, 007 Venture Partners Investor post
Jun 2026 Seed, per Dealroom and Preqin Not disclosed Tekedia Capital; gumi Inc. listed by Preqin as a current investor Deal intelligence

What the filings show

No Form D notice for Anto Biosciences, Inc. appears in a search of SEC EDGAR company filings run under the name “Anto” on September 25, 2026. The search returned twelve companies whose names begin with that string, none of them Anto Biosciences. No CIK for the company could be located this way, and no Form D filed by an SPV or fund with “Anto” in its name was found either. That does not mean no capital has moved. Companies that raise under Section 4(a)(2), or through instruments other than the type of offering Regulation D was built for, can leave no Form D on file at all.

Reading the filings

  1. The investor lists do not match.A 007 Venture Partners LinkedIn post, describing the firm’s sixth investment, names five other co-investors: Y Combinator, Massive Tech Ventures, Ritual Capital, RRE Ventures, and Standard Partners. Months later, Dealroom and Preqin describe a seed round tied to Tekedia Capital and dated to June 2026, and Preqin separately lists gumi Inc. as a current investor. Neither report mentions the other’s investors by name.
  2. No dollar figure is confirmed anywhere.Every source reviewed, the company’s own site, Y Combinator, the two investor announcements, and three aggregator profiles, describes a seed round without stating its size. One aggregator, Extruct AI, headlines the company’s page with a one million dollar funding figure, but does not cite a filing or an announcement that states that number, so it is treated here as unconfirmed.
  3. The absence of a Form D is itself a data point.A company that has closed institutional checks from five or more named venture firms would ordinarily be expected to file a Form D within fifteen days of a first sale of securities under Regulation D. None appears under the company’s name as of this page’s data date, which either means the filing has not yet been made, the raise used a different legal name, or it proceeded under an exemption that does not require one.
  4. Two announcements, seven months apart, may describe one round or two.The 007 Venture Partners post and the Tekedia-linked coverage could describe the same seed round being built out over time with different investors joining at different points, or two distinct rounds. Nothing in the public record settles which.

Commercial signals

Signal Detail Source type
Accelerator Y Combinator Fall 2025 batch, active status, primary partner Nicolas Dessaigne. YC data
Research base Founders hold active research affiliations at the Broad Institute of MIT and Harvard, MIT’s Traverso Lab, and prior roles at Harvard Medical School and Johnson & Johnson. Independent
Publications One peer reviewed journal paper (Clinical Pharmacology & Therapeutics, 2025) and multiple preprints and workshop papers predate or accompany the company. Public record
Customers Company says it is working with pharma research and development teams. No partner is named. Company-stated
Federal funding No NIH or NSF award naming Anto Biosciences was found in a records search. Not found

What to watch

  • A Form D filing, or an amended one, that states an actual dollar amount for the seed round.
  • Confirmation of whether the 007 Venture Partners and Tekedia Capital announcements describe one round or two.
  • A named pharma partner or licensing deal, which would be the first outside validation of the platform.
  • Any move to a Series A, which would typically bring its own Form D.

The Anto Biosciences story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Anthrogen: Shared investor: Ritual Capital. A San Francisco lab that set out to engineer carbon-eating bacteria and has become a protein foundation model company, now shipping a 102 billion parameter model called
  • Granza Bio: Shared investor: Ritual Capital. A San Francisco biotech trying to turn the immune system's own cell killing machinery into a programmable drug platform
  • Avelis Health: Shared investor: Tekedia Capital. A Y Combinator startup that started by fighting patients’ medical bills, then pivoted to auditing every claim for self-insured employers before the money moves
  • Fortuna Health: Shared investor: Rre Ventures. A consumer app for getting onto Medicaid and staying on it, paid for by the hospitals and health plans that lose money when coverage lapses

Sources

  1. Public recordSEC EDGAR company search, companies matching “Anto,” Form DSEC · accessed Sep 25, 2026
  2. Public recordPubMed record, Emerging Tools and Technologies for Microbiome-Aware Drug DevelopmentClinical Pharmacology & Therapeutics, doi 10.1002/cpt.70026 · 2025
  3. YC dataAnto Biosciences: A Foundation Model for Microbial CommunitiesY Combinator company profile · 2025
  4. InvestorAnto Biosciences Raises Seed Round for Microbiome Modeling007 Venture Partners, LinkedIn post · 2026
  5. IndependentTekedia Capital invests in Anto Biosciences to make the gut microbiome computableDealroom.co · Jun 2026
  6. IndependentAnto Biosciences, Inc. asset profilePreqin · 2026 listing
  7. IndependentAnto Biosciences funding profileExtruct AI · accessed Sep 18, 2026
  8. IndependentAnto Biosciences company profileStartup Intros · accessed Jul 13, 2026
  9. IndependentAnto Biosciences Inc, company profileBloomberg Markets · accessed 2026
  10. CompanyAnto Biosciences homepage and team pageanto.bio · accessed Sep 25, 2026

Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Anto Biosciences. This page is not an offer to sell or a recommendation to buy any security.